Last reviewed · How we verify
Empagliflozin 10 MG
At a glance
| Generic name | Empagliflozin 10 MG |
|---|---|
| Also known as | Jardiance, Empagliflozin, EMPAA, Horizon,, Gliflozin |
| Sponsor | Tanta University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Antithrombotic Activities of Sotagliflozin vs. Empagliflozin (PHASE4)
- SGLT2i Therapy in Islet Transplantation (SIT) (PHASE4)
- A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension (PHASE1)
- Effects of SGLT2 Inhibitors on Erythropoiesis in Heart Failure
- The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity (PHASE4)
- Empagliflozin Adjunctive Therapy in Bipolar Depression (NA)
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (PHASE1, PHASE2)
- Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Empagliflozin 10 MG CI brief — competitive landscape report
- Empagliflozin 10 MG updates RSS · CI watch RSS
- Tanta University portfolio CI